NICE - Endorsed Technology Appraisals 2020/2021

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2020/2021

The following technology appraisals have been endorsed during 2020/21. Information on technology appraisals endorsed in previous years can be found on the homepage. 

September 2020

TA644 - Entrectinib for treating NTRK fusion-positive solid tumours

TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer

TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia

TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant

August 2020

TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer

TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

 

July 2020

TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis

TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

TA631 - Fremanezumab for preventing migraine

TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours

NICE TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab Note this guidance updates and replaces NICE Technology Appraisal TA472, which was endorsed by the DoH in January 2019.

NICE TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

NICE TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma

NICE TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

 

Back to top